Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13366831 | 1.00 | NPSR1 (0.68) | NPSR1KDM4EMAPTHPGDHTT | |
| Tegavivint SCHEMBL14947676 | 1.00 | NPSR1 (0.68) | NPSR1KDM4EMAPTHPGDHTT | |
| Tegavivint SCHEMBL29489537 | 1.00 | NPSR1 (0.68) | NPSR1KDM4EMAPTHPGDHTT | |
| Tegavivint SCHEMBL29372288 | 1.00 | NPSR1 (0.68) | NPSR1KDM4EMAPTHPGDHTT | |
| Tegavivint SCHEMBL31694538 | 1.00 | NPSR1 (0.68) | NPSR1KDM4EMAPTHPGDHTT | |
| SCHEMBL20302801 | 0.97 | KDM4E (0.72) | NPSR1KDM4EMAPTHPGDHTT | |
| SCHEMBL18426421 | 0.95 | NPSR1 (0.62) | NPSR1KDM4EMAPTHPGDHTT | |
| SCHEMBL61341 | 0.92 | NPSR1 (0.59) | NPSR1KDM4EMAPTHPGDHTT | |
| SCHEMBL18418019 | 0.92 | NPSR1 (0.59) | NPSR1KDM4EMAPTHPGDHTT | |
| SCHEMBL18422347 | 0.91 | MAPT (0.58) | NPSR1KDM4EMAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793759-B2 | Lyophilized formulations of tegavivint | Iterion Therapeutics, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793759-B2 | Lyophilized formulations of tegavivint | Iterion Therapeutics, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11571388-B2 | Lyophilized formulations of tegavivint | Iterion Therapeutics, Inc. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230012615-A1 | METHODS FOR TREATMENT OF FIBROTIC DISEASES | Iterion Therapeutics, Inc. | 2023-01-19 | — | — | US | disclosed |
| US-20220184051-A1 | FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDS | Iterion Therapeutics, Inc. | 2022-06-16 | — | — | US | disclosed |
| WO-2022115434-A1 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT | Iterion Therapeutics, Inc. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220160637-A1 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT | Iterion Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220160636-A1 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT | Iterion Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220160635-A1 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT | Iterion Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-9963475-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963475-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| EP-2152258-B1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2010059142-A1 | ANTHRAQUINONE DIOXIMES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160636-A1 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT | TTPA, CCNT2, TP53 | NPSR1 3595/4885KDM4E 1387/4885MAPT 524/4885 |
| US-20220184051-A1 | FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDS | UGT1A10, TTPA, UGT1A7 | NPSR1 3286/4885KDM4E 1927/4885MAPT 246/4885 |
| US-11793759-B2 | Lyophilized formulations of tegavivint | TTPA, CCNT2, TP53 | NPSR1 3595/4885KDM4E 1387/4885MAPT 524/4885 |
| US-20220160637-A1 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT | TTPA, CCNT2, TP53 | NPSR1 3595/4885KDM4E 1387/4885MAPT 524/4885 |
| US-20230012615-A1 | METHODS FOR TREATMENT OF FIBROTIC DISEASES | NR1H3, NR1H2, NR1H4 | NPSR1 147/4885KDM4E 2588/4885MAPT 4883/4885 |
| US-11571388-B2 | Lyophilized formulations of tegavivint | TTPA, CCNT2, TP53 | NPSR1 3595/4885KDM4E 1387/4885MAPT 524/4885 |
| US-20220160635-A1 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT | TTPA, CCNT2, TP53 | NPSR1 3595/4885KDM4E 1387/4885MAPT 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.